Back to Sectors

VYCO

VYCOR MEDICAL INC
3 filings tracked
healthcaremedical devicesMICRO (<$300M)

Signal Magnitude Chart

BULLISH | 70% | 3/31/2026 | margin expansionBEARISH | 90% | 3/31/2026 | debt restructureBEARISH | 60% | 3/31/2026 | management changeBULLISH | 70% | 5/15/2026 | earnings beatBULLISH | 80% | 5/15/2026 | margin expansionBEARISH | 60% | 5/15/2026 | dilution riskNEUTRAL | 40% | 5/15/2026 | debt restructureBULLISH | 70% | 5/15/2026 | earnings beatBULLISH | 80% | 5/15/2026 | margin expansionBEARISH | 60% | 5/15/2026 | dilution riskNEUTRAL | 40% | 5/15/2026 | debt restructureMar 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

bullishMay 15

Company swung from an operating loss to an operating income of $45,808.

earnings beat
70%
bullishMay 15

Maintained high gross margins of 82% while reducing SG&A expenses.

margin expansion
80%
bearishMay 15

Convertible notes could result in the issuance of over 4 million shares.

dilution risk
60%
neutralMay 15

Heavy reliance on related-party notes and accrued interest to sustain operations.

debt restructure
40%
bullishMay 15

Company swung from an operating loss to an operating income of $45,808.

earnings beat
70%
bullishMay 15

Maintained high gross margins of 82% while reducing SG&A expenses.

margin expansion
80%
bearishMay 15

Convertible notes could result in the issuance of over 4 million shares.

dilution risk
60%
neutralMay 15

Heavy reliance on related-party notes and accrued interest to sustain operations.

debt restructure
40%
bullishMar 31

Core neurosurgical segment maintains high gross margins above 83%.

margin expansion
70%
bearishMar 31

Severe working capital deficit and reliance on high-interest related-party debt.

debt restructure
90%
bearishMar 31

Material weakness in internal controls due to lack of independent audit committee.

management change
60%

Filing History

10-QMay 15, 2026

The Q1 2026 filing presents a stark contrast between operational viability and balance sheet insolvency. On one hand, the core Vycor Medical business has proven it can generate a profit and positive cash flow, suggesting the underlying product market is healthy. On the other hand, the company is burdened by a legacy of debt and a stockholders' deficiency that raises substantial doubts about its ability to continue as a going concern. The ultimate trajectory for investors depends on whether management can successfully execute its 'cleanup' phase—specifically the monetization of NovaVision and the potential uplisting of the stock. If the company can bridge its liquidity gap without catastrophic dilution, the high-margin nature of the neurosurgery business provides a path to recovery. However, the current reliance on related-party loans and the lack of a functioning audit committee introduce significant governance risks that may overshadow the operational gains.

10-KMar 31, 2026

The 10-K reveals a company at a critical crossroads, where a high-performing product is trapped within a distressed corporate structure. The Vycor Medical division is clearly a viable business with strong margins and growing demand, yet the consolidated entity is burdened by the failure of the NovaVision segment and a legacy of insider-driven debt. The tension between the operational success of the VBAS system and the systemic financial instability of the parent company creates a binary outcome for investors. The path forward depends entirely on management's ability to secure new capital or execute a strategic sale/partnership through Maxim Group. While the operational metrics of the neurosurgical unit are encouraging, they are currently insufficient to offset the structural deficits of the balance sheet. Until the company resolves its going-concern status and addresses its governance deficiencies, the intrinsic value of the surgical business remains obscured by high insolvency risk.